FDA Staff Back Celltrion's Remicade Biosimilar
U.S. Food and Drug Administration staff on Friday voiced support for Celltrion's proposed biosimilar of Janssen Biotech's Remicade, keeping it on track to become the second and most complex U.S. biosimilar....To view the full article, register now.
Already a subscriber? Click here to view full article